All companies
Visit website
Advanced Aesthetic Technologies, Inc.
OperatingFounded 2014
Advanced Aesthetic Technologies Inc. is transforming the global aesthetic medical device market with its 100% natural Algeness® dermal filler, the culmination of 10 years of scientific and clinical research.
Latest valuation
—
No round has disclosed a priced valuation or cap.
Total raised
$78,120
Across 2 rounds since 2018
Latest share price
$2.50
Advanced Aesthetic Technologies, Inc. Stock 1 offering price
Financials
FY2016–FY2017 · from SEC filings · hover any figure for its source$192K
$983K
2016
$303K
$1.1M
2017
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2016
FY2017
Income statement
Revenue
$192,052
$303,210
Cost of goods sold
$96,136
$177,685
Gross margin
50%
41%
Net income
$982,694
$1,114,087
Taxes paid
$0
$0
Balance sheet
Cash
$12,067
$34,449
Accounts receivable
$31,342
$85,406
Total assets
$597,652
$907,959
Short-term debt
$0
$0
Long-term debt
$0
$0
Total liabilities
$0
$0
Other
Headcount
—
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Fundraising history
Raised — / $1.1M
Raised $78.1K / $1.1M
Reg CF annual-report compliance
Not requiredFiled Form C-TR (terminated reporting)
Filed 1 of 8 annual reports (FY2018–FY2025)
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001651778Share price $2.50
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.